Skip to content
OpenCapital
Get started

Bristol-Myers Squibb BMY Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Incyte logo
IncyteINCY
$3.98B+104%
Gilead Sciences logo
Gilead SciencesGILD
$7.63B-3.8%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$49.52M-40.7%

Other financials

Income statement

See full
Revenue$11.5B+2.6%
Gross profit$8.1B-1.2%
Net income$2.7B+9.0%
EPS (diluted)$1.31+9.2%

Balance sheet

See full
Total debt$44.7B-10.5%
Total equity$20.1B+15.4%
Total assets$86.5B-6.4%

Cash flow

See full
Operating cash flow$1.1B-43.5%
CapEx$347.0M+33.5%
Free cash flow$757.0M-55.3%

Valuation

See full
Market cap$126.79B+31.1%
Enterprise value$161.88B+21.3%
P/E17.4×-2.0×
P/S2.6×+0.6×

Profitability

See full
Gross margin70.5%0.0pp
Net margin15%+3.8pp
FCF margin24.6%-2.9pp

Returns & leverage

See full
Return on equity38.8%+7.3pp
Debt / equity2.2×-0.6×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bristol-Myers Squibb's cash & equivalents?
Bristol-Myers Squibb (BMY) reported cash & equivalents of $9.57B in Q1 2026.
How has Bristol-Myers Squibb's cash & equivalents changed year-over-year?
Bristol-Myers Squibb's cash & equivalents decreased by 12.0% year-over-year, from $10.88B to $9.57B.
What is the long-term trend for Bristol-Myers Squibb's cash & equivalents?
Over 5 years (2020 to 2025), Bristol-Myers Squibb's cash & equivalents has grown at a -7.4% compound annual growth rate (CAGR), from $14.97B to $10.21B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.